A comparison of the two evaluation methods according to the ASCO/CAP guidelines for BC and GC showed that the evaluation scheme according to the guidelines for the GC was significantly more sensitive in the detection of the ERBB2-amplified UTUCs. Here, ERBB2 is linked to breast cancer.